Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives

Archives of Gynecology and Obstetrics

Volumn 293, Issue 2, 2016, Pages 239-246

  Vrachnis, Nikolaos ^a   Iavazzo, Christos ^a   Iliodromiti, Zoe ^a   Sifakis, Stavros ^b   Alexandrou, Andreas ^c   Siristatidis, Charalambos ^d   Grigoriadis, Charalambos ^a   Botsis, Dimitrios ^a   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Diabetes mellitus; Endometrial cancer; Hyperinsulinemia; Insulin resistance; Ovarian cancer

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN GLARGINE; METFORMIN; STEROID HORMONE; INSULIN DERIVATIVE;

APOPTOSIS; BREAST CANCER; CALORIC INTAKE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; COCHRANE LIBRARY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENERGY EXPENDITURE; EPIDEMIOLOGICAL DATA; FEMALE GENITAL TRACT CANCER; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INFORMATION RETRIEVAL; INSULIN RESISTANCE; MEDLINE; MITOGENESIS; NARRATIVE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR CELL; DIABETES COMPLICATIONS; ENERGY METABOLISM; FEMALE; GENITAL NEOPLASMS, FEMALE; HYPERINSULINISM; INCIDENCE; PATHOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

DIABETES COMPLICATIONS; DIABETES MELLITUS; ENERGY METABOLISM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; INSULINS; METFORMIN; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84954387926     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3858-z     Document Type: Review

References (75)

1. Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3:1060–1065
2. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625
3. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511
4. Abdel-Hamid NM, Nazmy MH, Abdel-Ghany MI, Nazmy WH (2012) Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes. Ann Hepatol 11:118–127
5. Zhong Y, Li J, Chen Y, Wang J et al (2012) Activation of endoplasmic reticulum stress by hyperglycemia is essential for muller cell-derived inflammatory cytokine production in diabetes. Diabetes 61:492–504
6. Di Bartolo BA, Chan J, Bennett MR et al (2012) TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe−/− mice. Diabetologia 54:3157–3167
7. Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106:1319–1331
8. Zhu W, Jia Q, Wang Y et al (2012) The anthocyanin cyanidin-3-O-β-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway. Free Radic Biol Med 52:314–327
9. Schultze SM, Hemmings BA, Niessen M, Tschopp O (2012) PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 11(14):e1
10. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
11. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
12. Gapstur SM, Gann PH, Lowe W et al (2000) Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283:2552–2558
13. Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:823–835
14. Hjartåker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630:72–93
15. Liao DJ, Dickson RB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80:175–189
16. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332
17. Key TJ (1999) Serum oestradiol and breast cancer risk. Endocr Relat Cancer 6:175–180
18. Cho LW, Kilpatrick ES, Keevil BG et al (2011) Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls. Horm Metab Res 43:141–145
19. Persson I, Weiderpass E, Bergkvist L et al (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10:253–260
20. Rutanen EM (1998) Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12:399–406
21. Lukanova A, Lundin E, Micheli A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108:425–432
22. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786
23. Kaaks R (1996) Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 7:605–625
24. Wolf I, Sadetzki S, Catane R et al (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111
25. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244
26. Kluge A, Zimmermann R, Munkel B et al (1995) Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res 29:407–415
27. Becker S, Dossus L, Kaaks R (2009) Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 115:86–96
28. Nestler JE (2000) Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 24:71–73
29. Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91–106
30. Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response the evidence mounts. J Leukoc Biol 86:505–512
31. Jemal A, Tiwari CG, Murray T et al (2004) Cancer statistics. Cancer J Clin 54:8–29
32. Coughlin SS, Calle EE, Teras LR et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167
33. Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374
34. Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG et al (2000) Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11:707–711
35. Xu WH, Matthews CE, Xiang YB et al (2005) Effect of adiposity and fat distribution on endometrial cancer risk in Shanghai women. Am J Epidemiol 161:939–947
36. Berstein LM, Kvatchevskaya JO, Poroshina TE et al (2004) Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol 130:687–693
37. Gnacinska M, Malgorzewicz S, Stojek M et al (2009) Role of adipokines in complications related to obesity: a review. Adv Med Sci 54:150–157
38. Hanley AJ, Bowden D, Wagenknecht LE et al (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 92:2665–2671
39. Finucane FM, Luan J, Wareham NJ et al (2009) Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52:2345–2349
40. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka K (2010) Serum leptin–adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 119:65–69
41. Dal Maso L, Augustin LS, Karalis A et al (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163
42. Painter JN, O’Mara TA, Batra J et al (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 24:1478–1492
43. Spurdle AB, Thompson DJ, Ahmed S et al (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43:451–454
44. Gogas H, Shapiro F, Aghajanian C et al (1996) The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22–26
45. Fasching PA, Gayther S, Pearce L et al (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2:171–181
46. Lee AW, Tyrer JP, Doherty JA et al (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol 136:542–548
47. Parazzini F, Moroni S, La Vecchia C et al (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33:1634–1637
48. Weiderpass E, Ye W, Vainio H et al (2002) Diabetes mellitus and ovarian cancer. Cancer Causes Control 13:759–764
49. Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548–555
50. Bakhru A, Buckanovich R, Griggs J (2011) The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 121:106–111
51. Bordeleau L, Lipscombe L, Lubinski J, Hereditary Breast Cancer Clinical Study Group et al (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117:1812–1818
52. Yakar S, Pennisi P, Zhao H, et al (2004) Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse. Novartis Found Symp 262:3–9 (discussion 9–18, 265–268)
53. Seldin DC, Landesman-Bollag E, Farago M et al (2005) CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 274:63–67
54. Wideroff L, Gridley G, Mellemkjaer L et al (1989) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365
55. Weiss HA, Brinton LA, Potischman NA et al (1999) Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 28:816–823
56. Talamini R, Franceschi S, Favero A et al (1997) Selected medical conditions and risk of breast cancer. Br J Cancer 75:1699–1703
57. Jee SH, Ohrr H, Sull JW et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202
58. Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952
59. Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diab Care 30:561–567
60. Mink PJ, Shahar E, Rosamond WD et al (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352
61. Kabat GC, Kim M, Caan BJ et al (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:2704–2710
62. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862
63. Cantrell LA, Zhou C, Mendivil A et al (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116:92–98
64. Romero IL, McCormick A, McEwen KA et al (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119:61–67
65. Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15:166–178
66. Abe R, Yamagishi S (2008) AGE–RAGE system and carcinogenesis. Curr Pharm Des 14:940–945
67. Hirsch HA, Iliopoulos D, Tsichlis PN et al (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511
68. Gotlieb WH, Saumet J, Beauchamp MC et al (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110:246–250
69. Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diab Care 32:1620–1625
70. Goodwin PJ, Stambolic V, Lemieux J et al (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215–220
71. Teng JA, Hou RL, Li DL et al (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43:519–523
72. Jonasson JM, Ljung R, Talback M et al (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:1745–1754
73. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765
74. Kim HJ, Kwon H, Lee JW et al (2015) Metformin increases survival in hormone receptor-positive, Her2-positive breast cancer patients with diabetes. Breast Cancer Res 17:64
75. Oppong BA, Pharmer LA, Oskar S et al (2014) The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3:1025–1034